Table. 1.

Table. 1.

Selected reports on allogeneic hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis

Study/author Year N Major conditioning regimen VOD
(n or %)
Mixed chimerism GVHD TRM Survival Ref

Acute (grade) Chronic
Myeloablative conditioning (MAC)
HLH-94/Horne 2005 86 Bu, Cy, VP 4 (dead) 19% 32% (2-4) 9% 30% 64% (3y) 12
Baker 2008 91 Bu, Cy, VP±ATG 18% 11% 41% (2-4) 25% 35% 52% (1y), 45% (3y) 20
AIEOP/Cesaro 2008 61 Bu, Cy±VP 7 (severe) 15% 31% (2-4) 17% 26% 59% (8y) 21
Japan/Ohga 2010 43 Bu, Cy, VP±ATG NS 19% NS NS 17% 65% (10y) 22
Korea/Seo 2010 19 Bu, Cy, VP±ATG 2 NS 26% (2-4) NS 20% 75% (5y) 23
CCHMC/Marsh 2010 14 Bu, Cy ATG±VP 0 18% 14% (2-3) NS 57% 43% (3y) 13
Reduced intensity conditioning (RIC)
UK/Cooper 2006 12 Flu, Mel, Alem or ATG 0 33% 33% (2-4) 33% NS 75% (2.5y) 24
UK/Cooper 2008 25 Flu, Mel, Alem or ATG 0 29% NS NS NS 84% (3y) 26
CCHMC/Marsh 2010 26 Flu, Mel, Alem 0 65% 8% (2-3) NS 12% 92% (3y) 13
USA/Allen 2018 34 Flu, Mel, Alem 0 59%* 27% (2-4) NS ∼29% 82% (1y), 68% (1.5y) 25

*Patients with mixed chimerism or received additional interventions.

Bu, busulfan 16 mg/kg; Cy, cyclophosphamide 120-200 mg/kg; VP, etoposide 30 mg/kg or 900 mg/m2; ATG, antithymocyte globulin; Flu, fludarabine 150 mg/m2; Mel, melphalan 140 mg/m2; Alem, alemtuzumab; VOD, veno-occlusive disease; TRM, transplant-related mortality; NS, not specified; Ref, reference.

Clin Pediatr Hematol Oncol 2021;28:28-38
© 2021 Clin Pediatr Hematol Oncol